ARTICLE DOWNLOAD

Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis

10$
ARTICLE DOWNLOAD

Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis

10$

Yang Ni, Xin Ye, Xia Yang, Guanghui Huang, Wenhong Li, Jiao Wang, Xiaoying Han, Zhigang Wei, Min Meng & Zhigeng Zou 

Abstract

Aims

Local therapy including surgery or radiotherapy has been reported for the treatment of non-small cell lung cancer (NSCLC) with synchronous solitary metastasis, while studies with other local ablative treatment are rare. Here, we summarized our single-center experience of microwave ablation (MWA) for both primary and metastatic lesions in NSCLC patients with synchronous solitary extracranial metastases.

Patients and methods

We retrospectively screened our institute database from January 2014 to Jun 2019. NSCLC patients with synchronous extracranial solitary metastasis with primary and metastatic lesions that were treated with MWA were identified and analyzed.

Results

Of the 1472 stage IV NSCLC patients found, 38 were diagnosed with synchronous extracranial solitary metastasis and 29 of them received MWA for primary and metastatic lesions. The most common distant metastases were contralateral lung metastases (14 cases), followed by bone (6), liver (4), adrenal gland (3) and pleura metastases (1). Median OS and PFS was 21.5 and 12.5 months, respectively. Patients with N0 had significantly longer PFS (median 18.5 vs. 8.0 months) and OS (median 42.7 vs. 19.0 months). In addition, systemic therapy was showed to be a prognostic factor for better PFS (12.9 vs. 7.5 months). Clinical pathological factors including age, histology, T stage, PS score, and metastasis locations are not significantly associated with survival.

Conclusions

MWA may serve as an alternative treatment for NSCLCs with synchronous solitary extracranial metastases.

Only units of this product remain
Year 2020
Language English
Format PDF
DOI 10.1007/s00432-020-03176-z